GroundRules
Browse Indiana
Read the original sections, or search by topic.
- IC 16-42-19-30 · Investigation of suspected legend drugs; records
- IC 16-42-20-1 · Powers of enforcement officers
- IC 16-42-20-2 · "Controlled premises" defined; administrative inspections and warrants
- IC 16-42-20-3 · Injunctions
- IC 16-42-20-4 · Cooperative arrangements and confidentiality
- IC 16-42-20-5 · Forfeitures
- IC 16-42-20-6 · Burden of proof; liabilities
- IC 16-42-20-7 · Judicial review
- IC 16-42-20-8 · Education programs
- IC 16-42-20-9 · Research
- IC 16-42-20-10 · Contracts for educational and research activities
- IC 16-42-20-11 · Anonymity of research subjects
- IC 16-42-20-12 · Possession and distribution of controlled substances for research purposes
- IC 16-42-21-1 · "Controlled substance"
- IC 16-42-21-2 · "Drug sample"
- IC 16-42-21-3 · "Practitioner"
- IC 16-42-21-4 · Delivery of drug samples to ultimate user after removal from original packaging or after expiration date; offense
- IC 16-42-22-1 · "Brand name"
- IC 16-42-22-2 · Repealed
- IC 16-42-22-3 · "Customer"
- IC 16-42-22-4 · "Generically equivalent drug product"
- IC 16-42-22-4.5 · "Practitioner"
- IC 16-42-22-5 · "Substitute"
- IC 16-42-22-5.5 · Limitation of effect of chapter
- IC 16-42-22-6 · Prescription forms
- IC 16-42-22-7 · Repealed
- IC 16-42-22-8 · Requirements for substitution
- IC 16-42-22-9 · Transmission of practitioner's instructions to pharmacist
- IC 16-42-22-10 · Substitution prohibited
- IC 16-42-22-11 · Substitution of generic drugs; identification of brand name drug
- IC 16-42-22-12 · Identification of manufacturer or distributor of dispensed drug product on prescription
- IC 16-42-22.5-0.5 · Applicability
- IC 16-42-22.5-1 · "Bulk drug substance"
- IC 16-42-22.5-2 · "Compounding"
- IC 16-42-22.5-3 · Requirements to engage in compounding; nonresident pharmacies; maintenance of records
- IC 16-42-22.5-4 · Compliance with federal laws
- IC 16-42-22.5-5 · Indiana board of pharmacy with primary authority to investigate
- IC 16-42-22.5-6 · Report; requirements; posted on websites; submission to legislative council
- IC 16-42-23-1 · Health care facilities; restrictions on use
- IC 16-42-23-2 · Disciplinary action against attending physician
- IC 16-42-23-3 · Prescription or administration permitted with written informed request
- IC 16-42-23-4 · Construction of chapter
- IC 16-42-23-5 · Written informed request form
- IC 16-42-23-6 · Regulation of use, sale, prescription, manufacture, or distribution within state
- IC 16-42-23-7 · Required manufacture, sale, distribution, or prescription
- IC 16-42-23-8 · Federal funding of health care facilities
- IC 16-42-24-1 · Record of use
- IC 16-42-24-2 · Administration restricted
- IC 16-42-24-3 · Hospital's restricting or forbidding use prohibited; conditions
- IC 16-42-24-4 · Disciplinary action against attending physician prohibited if use requested by patient
- IC 16-42-24-5 · Use permitted in place of other therapies if requested by patient
- IC 16-42-24-6 · Construction of chapter
- IC 16-42-24-7 · Use request form
- IC 16-42-24-8 · Regulation of manufacture, distribution, sale, or use
- IC 16-42-24-9 · Manufacture, sale, distribution, or prescription not required
- IC 16-42-24-10 · Use prohibition by health care facility facing loss of federal funding
- IC 16-42-25-1 · "Biological product"
- IC 16-42-25-2 · "Biosimilar"
- IC 16-42-25-3 · "Interchangeable"
- IC 16-42-25-4 · Substitution; conditions
- IC 16-42-25-5 · Records of dispensing biologic product; time frame; exception
- IC 16-42-25-6 · Record retention; pharmacy; prescribing practitioner
- IC 16-42-25-7 · Link to current list of interchangeable biological products; rules
- IC 16-42-25-8 · Compliance with prescription requirements
- IC 16-42-26-1 · Effect on clinical trial laws; availability
- IC 16-42-26-2 · "Investigational drug, biological product, or device"
- IC 16-42-26-3 · "Qualified patient"
- IC 16-42-26-4 · Availability of investigational drug, biological product, or device
- IC 16-42-26-5 · Causes of action
- IC 16-42-26.5-1 · "Eligible facility"
- IC 16-42-26.5-2 · "Individualized investigational treatment"
- IC 16-42-26.5-3 · "Life threatening or severely debilitating disease"
- IC 16-42-26.5-4 · Qualification requirements
- IC 16-42-26.5-5 · Written informed consent
- IC 16-42-26.5-6 · Availability of individualized investigational treatment
- IC 16-42-26.5-7 · Liability for outstanding debt
- IC 16-42-26.5-8 · Prohibition on disciplinary actions for recommending individualized investigational treatment
- IC 16-42-26.5-9 · Effect on clinical trial laws
- IC 16-42-27-1 · "Prescriber"
- IC 16-42-27-2 · Prescribing or dispensing of overdose intervention drug without examination; requirements; administration of drug; exemption from practice of medicine; entities acting under standing order; statewide standing order; immunity from prosecution
- IC 16-42-27-3 · Immunity of provider, pharmacist, individual, entity
- IC 16-42-28-1 · "Local health department"
- IC 16-42-28-2 · "Mobile retail food establishment"
- IC 16-42-28-3 · "Mobile retail food establishment license"
- IC 16-42-28-4 · State department duties
- IC 16-42-28-5 · License application; fees
- IC 16-42-28-6 · License; renewal; operation
- IC 16-42-28-7 · Local permit, license, or fee not required
- IC 16-42-28-8 · Local health department duties; license requirement
- IC 16-42-28-9 · Rules
- IC 16-42-28-10 · Establishment of workgroup; membership
- IC 16-44-1-1 · Labeling requirements; advertisements; violations
- IC 16-44-1-2 · Injunction
- IC 16-44-1-3 · Temporary injunction; prohibition; right to hearing
- IC 16-44-1-4 · Injunction; purpose
- IC 16-44-2-0.5 · "Avgas"
- IC 16-44-2-1 · "Gasoline"
- IC 16-44-2-1.5 · "Jet fuel"
- IC 16-44-2-2 · "Kerosene"
- IC 16-44-2-2.4 · "MTBE"